Julphar maintains sales growth after successful market re-entry across GCC

Gulf Pharmaceutical Industries (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has reported its financial results for the third quarter of 2020.

In third quarter, the company generated Dh186.9 million in sales, an increase quarter on quarter by 10 per cent, credited to the successful market re-entry in Saudi Arabia, Oman, Kuwait, and Bahrain following the lifting of the temporary export suspension into these countries earlier this year.

Julphar has also announced a net loss of Dh21.8 million, a substantial improvement since 2019, which is attributed to the increase in net sales, expense reduction and gross margin improvement.

In addition, the equity of the company has increased from Dh878 million to Dh1,267.1 million following the successful completion of the rights issue in July 2020, the group also reported substantial cost savings in selling and distribution expenses.

Sheikh Saqer Humaid Al Qasimi, Chairman of the board, Julphar, said it is reassuring to see the continued improvement in sales and the reduction of losses over the last quarter.

"We are confident that the success of the organisation to date is testimony to a promising future,” he said.

Dr Essam Farouk, chief executive officer of Julphar, said: “Our consistent progress repre-sents our efforts to achieve profitability and enhance our business performance. As leaders in pharmaceuticals we are always innovating, and this success will enable us to continue expanding our product portfolio and upgrade our existing facilities.”

During the previous period, Julphar also announced the appointment of a new chief commercial officer and the signing of a share sale agreement for Julphar Bangladesh Ltd, as the company continues its strategic turnaround project.

In future, Julphar will increase its activities towards building a robust product pipeline and improving operations efficiency.

— business@khaleejtimes.com